Regalasnow, Switzerland, May 24, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a pharmaceutical company in the clinical phase, a pioneer in the discovery and development of drugs based on allosteric modulation, announced today that Tim Dyer, CEO, will participate in the conference Benchmark Company Virtual Health Consultation on May 26, 2021 (09:00 – 16:30 EDT)
Mr. Dyer will be available for individual virtual meetings throughout the conference. For more information or to schedule an individual meeting with management, contact the conference representative or James@HaydenIR.com.
About Addex Therapeutics:
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of a new class of orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allostoric molecules and may offer an improved therapeutic approach to small “orthosthetic” molecules or conventional biological drugs. Addex’s allosteric modulating drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. The main candidate for the Addex product, dipraglurant (negative allosteric modulator mGlu5 or NAM), is about to initiate a clinical trial of fundamental registration for levodopa-induced dyskinesia (PD-LID) of Parkinson’s in 2Q 2021. Addex is also investigating the therapeutic use of dipraglurant in blepharospasm (a type of dystonia), for which a clinical trial is expected to begin during the second trimester of 2021. The third clinical program of Addex, ADX71149 (positive allosteric modulator mGlu2 or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a Phase 2 Clinical Trial Concept Test for the Treatment of Epilepsy in the Second quarter of 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC, focused on development for addiction treatment. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease, and mGlu3 PAM for neurodegenerative disorders. Addex shares are listed on the SIX Swiss Exchange and US depositary shares representing their shares are listed on the NASDAQ capital market and are listed under the symbol “ADXN” on each exchange.
This press release contains forward-looking statements within the meaning of the amended Private Securities Litigation Reform Act of 1995, as amended, including the planned initiation and progress of clinical trials and preclinical studies and their future funding activities. The words “can”, “want”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “pretend”, “believe”, “love”, “predict” “Project,” “potential,” “continue,” “goal,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statement in this press release is based on management’s current expectations and beliefs and is subject to a number of significant risks, uncertainties and factors that may cause actual events or results to differ materially from those expressed or implied by any advance. stated in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in the Company’s Annual Report on Form 20-F submitted to the SEC on March 11, 2021, as well as in market conditions and regulatory review.
Any forward-looking statement contained in this press release only represents the views of Addex Therapeutics as of the date of this document and should not be relied upon to represent its views as of any later date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except in accordance with the law.